Thus, our data showed a progressive decrease of diabetes duration, a higher rate of subjects with HbA1c < 7% and a reduction of those with HbA1c > 8%, among T2D subjects starting insulin therapy, when comparing the last vs. the first quinquennium. The gene discussed is INS; the disease is type 2 diabetes mellitus.